Novo Agrees Asset, License Deal With Omeros for Zaltenibart (1)

(Updates with additional details.)

• Novo Nordisk and Omeros enter into a definitive asset purchase and license agreement for the candidate drug zaltenibart in clinical development for rare blood and kidney disorders
• Under the terms of the agreement, Novo will get exclusive global rights to develop and commercialize zaltenibart in all indications
• Omeros is eligible to receive $340m in upfront and near-term milestone payments, up to a total of $2.1b including potential development and commercial milestones, plus tiered royalties on net sales
  • “Zaltenibart has a novel mode of action that could offer several advantages over other treatments for complement-mediated diseases,” says ...